Particulate Form (e.g., Powders, Granules, Beads, Microcapsules, And Pellets) Patents (Class 424/489)
  • Patent number: 11401252
    Abstract: The present invention relates to a method of producing furfural and extracting lignin from a hemi-cellulosic biomass solution comprising a total quantity of C5 sugars, comprising the steps of heating the hemi-cellulosic biomass solution to a temperature of at least about 200° C.; acidifying the hemi-cellulosic biomass solution with acid to produce the furfural in vapor phase; and condensing the furfural to recover furfural in solution, wherein the furfural is produced at a total molar yield of at least 70% of moles of furfural produced/the total moles C5 sugars present in the initial hemi-cellulosic biomass solution. Low molecular weight lignin can also be recovered from the hemi-cellulosic biomass solution prior to furfural production by membrane concentration, acidification, coagulation and filtration.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 2, 2022
    Assignee: FPInnovations
    Inventors: Naceur Jemaa, Adil Mazar, Waleed Wafa Al Dajani, Michael Paleologou
  • Patent number: 11395812
    Abstract: The present invention relates to a docetaxel albumin nanoparticle pharmaceutical composition, a preparation method therefor, and a use thereof for manufacturing drugs for treating cancer. The pharmaceutical composition comprises docetaxel, albumin and amino acid(s), wherein the weight ratio between albumin and docetaxel is no more than 50, preferably is 20:1 to 1:1, and the weight ratio between amino acid(s) and docetaxel is not less than 0.5, preferably is 1:1 to 20:1.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 26, 2022
    Inventors: Zhengxing Su, Likai Yang, Dong Zhao, Jing Zhou, Fengying Shan, Lichun Wang, Jingyi Wang
  • Patent number: 11389443
    Abstract: The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: July 19, 2022
    Inventor: Harry Ahdieh
  • Patent number: 11388930
    Abstract: An aerosol-generating article for producing an inhalable aerosol upon heating is provided, the article including a rod of an aerosol-generating substrate, the rod including from about 20 strands to about 200 strands of non-tobacco material including and configured to release at least one aerosol former, each strand of the strands having an equivalent diameter of at least about 0.1 mm, the strands being assembled such that the strands extend in a longitudinal direction of the rod; and a wrapper circumscribing the strands.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: July 19, 2022
    Assignee: Philip Morris Products S.A.
    Inventor: Tony Reevell
  • Patent number: 11382953
    Abstract: The purpose of the present invention is to provide a novel medicinal agent that has an effect of decreasing a microvascular blood flow. Provided is a microvascular blood flow decreasing agent that contains an immune checkpoint inhibitor.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: July 12, 2022
    Inventor: Tetsuji Okuno
  • Patent number: 11382917
    Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: July 12, 2022
    Inventors: Jinal Pandya, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Hiren Pansuriya
  • Patent number: 11376309
    Abstract: The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: July 5, 2022
    Assignee: Cerenis Therapeutics Holding S.A.
    Inventors: Jean-Louis Dasseux, Rose Ackermann, Daniela Carmen Oniciu
  • Patent number: 11376224
    Abstract: The present disclosure provides delivery systems for delivering FK506 locally to damaged nerve sites. Particulate FK506 incorporated into a fibrin gel, with the amount of FK506 sufficient to give an FK506 release rate over at least 14 days of at least 5 micrograms per milliliter of the treated tissue per day has been shown to remarkably improve axon regeneration. The delivery systems include particulate FK506 having sizes between about 500 microns to about 1 millimeter encapsulated in a fibrin matrix, powdered FK506 encapsulated within electrospun films, powdered FK506 encapsulated within a cellulose matrix, and a flexible film of small intestinal submucosa having a plurality of solid islands located on one side thereof, with each island containing a preselected amount of FK506 and a polyester.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: July 5, 2022
    Inventors: Kasra Tajdaran, Gregory Borschel, Tessa Gordon
  • Patent number: 11370896
    Abstract: An ionic nanocomposite comprising a nanomaterial comprising charged groups disposed on at least a portion of a surface of the nanomaterial and a polymer material comprising charged pendant group and/or end functionalized charged groups, where the charged groups of the nanomaterial and the charged pendant groups of the polymer material have opposite charges and the nanomaterial and polymer material are connected by one or more ionic bonds. A nanomaterial can be nanoparticles comprising sulfate groups disposed on at least a portion of the surface of the nanoparticles. The polymer material can be a polymer with pendant imidazolium groups. An ionic nanocomposite can be present as a film (e.g., a thin film). An ionic nanocomposite can be used in devices. A nanocomposite can be used in various coating application.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: June 28, 2022
    Inventors: Jérémy Odent, Emmanuel P. Giannelis, Jean-Marie Raquez, Philippe Dubois
  • Patent number: 11365397
    Abstract: Methods of screening rinse-off personal care compositions can include the use of explant skin in combination with measurements for moisture and/or cell proliferation.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: June 21, 2022
    Assignee: The Procter & Gamble Company
    Inventors: Karl Shiqing Wei, Teresa DiColandrea, Deborah Ruth Finlay
  • Patent number: 11366064
    Abstract: The present invention generally relates to improved methods for the manufacture of inhalation powders. More particularly, aspects of the disclosure relate to methods for in-line monitoring of powder blending by Raman spectroscopy.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: June 21, 2022
    Inventor: Hardik Kirtikumar Shah
  • Patent number: 11357830
    Abstract: Disclosed is a delivery device for delivering a payload, including a biological, chemical or biochemical substance, to a subject. The delivery device has a nanoparticle loaded with the payload, and porous coating structure over the loaded nanoparticle to prevent the payload from escaping the delivery device, while also preserving the activity of the payload and increasing effective utilization of the payload. Also disclosed is a delivery device for delivering a payload, including a natural virus, recombinant virus, or engineered virus. Also disclosed is a delivery device that has a liposome loaded with the payload and a biocompatible surface coating over the loaded liposome. Also disclosed are methods of fabricating the delivery devices and methods of using the delivery devices in treating health conditions, such as cancer, or in diagnostic applications.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: June 14, 2022
    Inventors: Sadik Esener, Negin Mokhtari, Mukanth Vaidyanathan, Ya-San Yeh, Ajay Sapre, Bartu Ahiska
  • Patent number: 11357736
    Abstract: The present invention relates treatments of a toxin in a subject. The toxin at least partially effects its toxicity in the subject via binding to a target cell of the subject. The present invention provides for methods, combinations and pharmaceutical compositions for decreasing or neutralizing the effect of a toxin in a subject, using, inter alia, an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, and an outer surface comprising a cellular membrane derived from a source cell. Exemplary toxins include acetylcholinesterase (AChE) inhibitors such as organophosphate poisoning.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: June 14, 2022
    Assignee: The Regents of the University of California
    Inventors: Liangfang Zhang, Zhiqing Pang, Ronnie H. Fang, Che-Ming Jack Hu
  • Patent number: 11355360
    Abstract: Disclosed are an underfill method and apparatus for a semiconductor package, the underfill method includes loading a substrate; charging a filler to be filled in between the substrate and a device; applying the filler to the substrate; and subjecting the applied filler to an electric field.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: June 7, 2022
    Assignee: ENJET CO., LTD.
    Inventors: Do Young Byun, Vu Dat Nguyen, Yong Hee Jang
  • Patent number: 11344557
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: May 31, 2022
    Assignee: Spruce Biosciences, Inc.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • Patent number: 11344028
    Abstract: The present disclosure describes a formulation including a nanoparticle including a polymer-associated strobilurin compound with an average diameter of between about 1 nm and about 500 nm; wherein the polymer is a polyelectrolyte, and a dispersant or a wetting agent. The disclosure describes various formulations and formulating agents that can be included in the formulations. Additionally, the disclosures describes application to various plants and fungi as well as advantages of the disclosed formulations.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: May 31, 2022
    Assignee: Vive Crop Protection Inc.
    Inventors: Fugang Li, Hung Hoang Pham, Rachel Gong, Henry Galas, Darren J. Anderson
  • Patent number: 11344498
    Abstract: Compositions and methods for administration of local anesthetics that are delivered by a single injection and enable repeated on-demand or high influx analgesia over extended periods have been developed. Pharmaceutical compositions including an effective amount of one or more sodium channel blockers including site 1 sodium channel blockers, optionally one or more alpha-2-adrenergic agonists, which are optionally encapsulated in liposomes, particles or microbubbles, and one or more triggerable elements are provided. The triggerable elements allow delivery of the encapsulated anesthetic drugs when an appropriate triggering stimuli are applied. Exemplary triggering agents or stimuli include near-infrared irradiation, UV- and visible light, ultrasound and magnetic field. In one embodiment, ultrasound is used to trigger a burst of microbubbles to enhance penetration of local anesthetic.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: May 31, 2022
    Inventors: Alina Y. Rwei, Changyou Zhan, Kathleen J. Cullion, Daniel S. Kohane
  • Patent number: 11338008
    Abstract: The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysine linking arm, and a pharmaceutical acceptable carrier. The composition has a pH less than 6.5, preferably has a pH about pH 2-5.5 The composition may comprise a pharmaceutical acceptable excipient such as mannitol, sorbitol, sucrose, lactose, or trehalose.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: May 24, 2022
    Inventor: David Chih-Kuang Chou
  • Patent number: 11337977
    Abstract: The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: May 24, 2022
    Assignee: Genentech, Inc.
    Inventors: Reinhard Reents, Pirmin Hidber, Andre Hell, Peter Steidle, Martin Wunderlich, Marie Pepelnjak, Francis Gosselin, Edward Yost
  • Patent number: 11318105
    Abstract: A method for preparing albumin nanoparticles based on free radical oxidation, comprising the following steps: preparing albumin aqueous solution with an albumin concentration of 1-20 mg/mL; (2) whilst stirring, adding free radical generating agent to the albumin aqueous solution, and continuing to stir and react for 1-60 min at 15-50° C.; the free radicals generated by the free radical generating agent are used for oxidizing the albumin, and the oxidized albumin molecules assemble to form albumin nanoparticles that are mainly bonded by hydrophobic action, thereby obtaining an albumin nanoparticle suspension. The present invention implements improvement by means of the key reaction mechanism of the nanoparticle preparation method and the corresponding design of the finishing process and, compared to the prior art, can effectively solve the problems of the complexity, high cost, and high toxicity of preparing nanoparticles.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: May 3, 2022
    Inventors: Jiangling Wan, Han Luo, Jianyong Sheng, Xiangliang Yang
  • Patent number: 11319415
    Abstract: A method for manufacturing resin particles is provided. The method includes the steps of: dissolving a resin free of poly(lactic-co-glycolic acid) (PLGA) in a good solvent of the resin to prepare a resin solution; and discharging the resin solution from at least one discharge hole having an inner diameter of less than 1,000 ?m into a poor solvent of the resin to form resin particles.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: May 3, 2022
    Assignee: Ricoh Company, LTD.
    Inventors: Tatsuru Moritani, Naoki Shiraishi, Tadahiko Morinaga
  • Patent number: 11320373
    Abstract: A system for identifying and optionally treating biological material is provided. The system includes a coherent light source for irradiating the biological material and device for collecting light waves reflected from the biological material and transforming the light waves to nanoplasmonic waves. The system also includes a processing module for extracting phase and amplitude information from the nanoplasmonic waves to identify the biological material based on the phase and amplitude information.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: May 3, 2022
    Inventors: Jacob Schneiderman, Moshik Cohen
  • Patent number: 11307197
    Abstract: Polyarginine-coated nanoparticle, and methods for making and using the nanoparticle. The nanoparticle can have a core that includes a material that imparts magnetic resonance imaging activity to the particle and, optionally, include one or more of an associated therapeutic agent, targeting agent, and diagnostic agent.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: April 19, 2022
    Assignee: University of Washington
    Inventors: Miqin Zhang, Omid Veiseh, Chen Fang, Forrest Kievit
  • Patent number: 11304986
    Abstract: A method for extracting bioactive compounds from plant materials using supercritical glycerin and at least one inert co-solvent that lowers the effective supercritical point of the supercritical glycerin to its boiling point, and the extracts obtained from the method.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: April 19, 2022
    Inventors: Demitri J Hopkins, Michael Willems
  • Patent number: 11304883
    Abstract: Polished talc microbeads, i.e. polished talc particles with a largest average diameter of less than 500 ?m and methods for the preparation thereof, which microbeads are especially suitable to be use as an alternative for plastic microbeads used in cosmetics and personal hygiene products. Body scrubs, tooth pastes and soaps comprising the present polished talc microbeads. The use of polished talc microbeads with a talc content of more than 70% (w/w) and a largest diameter of less than 500 ?m as a substitute for plastic microbeads in cosmetics and personal hygiene products.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: April 19, 2022
    Assignee: MONDO MINERALS B.V.
    Inventors: Jose Manuel De Barros Sanches, Tomasz Wasilewski, Anna Maria Kanios-Zakrzewska
  • Patent number: 11304898
    Abstract: A method of treating patients suffering from carcinoma of intrahepatic or extra hepatic bile duct or gall bladder which is locally advanced or metastatic, by intravenously administering to the patient, paclitaxel in the form of a nanodispersion. The nanodispersion comprises particles with a mean particle size less than 300 nm and is free of polyoxyethylated castor oil and free of a protein.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: April 19, 2022
    Inventors: Wen Wee Ma, Alex Adjei, Lynne Bui, Ronald Harning, Ajay Khopade, Subhas Bhowmick, Natarajan Arulsudar, Narendra Lakkad
  • Patent number: 11304902
    Abstract: The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: April 19, 2022
    Assignee: CURADIGM SAS
    Inventors: Agnes Pottier, Matthieu Germain, Laurence Poul, Marion Paolini, Marie-Edith Meyre
  • Patent number: 11298355
    Abstract: The invention relates to inhalable imatinib formulations, manufacture, and uses thereof.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: April 12, 2022
    Assignee: Aerovate Therapeutics, Inc.
    Inventors: Ben Dake, Ralph Niven, Andrew D. Levin
  • Patent number: 11292774
    Abstract: Provided is a method for the synthesis of N-protected 3,6-bis-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: April 5, 2022
    Assignee: MannKind Corporation
    Inventors: John J. Stevenson, Destardi Moye-Sherman
  • Patent number: 11285212
    Abstract: Described herein are carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a nitroboronic boronic acid and a linkage cleavable under reducing conditions, configured to present the polymer containing the nitroboronic acid to an environment external to the nanoparticle. Targeted versions of the described nanoparticles are also described, as are related compositions, methods and systems.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: March 29, 2022
    Assignee: California Institute of Technology
    Inventors: Mark E. Davis, Han Han
  • Patent number: 11285184
    Abstract: An aqueous alkaline composition comprising a cannabinoid which may be cannabidiol (CBD) used alone or in combination with other cannabinoids. An alkalizing agent which comprises pico size carbon particles is present in the composition, in an amount suitable for buffering the composition to a pH between about 7.5 and 9.5. The aqueous alkaline composition is stable and may be used in the preparation of a beverage or a pharmaceutical composition.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: March 29, 2022
    Inventor: Sreedhar Cheekoori
  • Patent number: 11278645
    Abstract: The present invention describes in vitro methods for producing a cellular composition with in vivo bone forming potential.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 22, 2022
    Inventors: Frank Luyten, Luis Freitas Mendes, Gabriella Nilsson Hall, Ioannis Papantoniou, Liesbet Geris
  • Patent number: 11278642
    Abstract: To provide a bioimplant capable of controlling a rate of an antibacterial agent and an antibiotic to be eluted from the coating film. An evanescent coating film made of a calcium phosphate-based material having crystallinity of 10% to 90% is formed at a predetermined area of the bioimplant and an antibacterial agent or an antibiotic is contained in the coating film to suppress adhesion of bacteria.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: March 22, 2022
    Inventors: Takao Hotokebuchi, Iwao Noda
  • Patent number: 11266659
    Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 8, 2022
    Inventors: Anna Rita Blanco, Maria Luisa Bondi', Gennara Cavallaro, Grazia Maria Letizia Consoli, Emanuela Fabiola Craparo, Gaetano Giammona, Mariano Licciardi, Giovanna Pitarresi, Giuseppe Granata, Patrizia Saladino, Clara La Marco, Irene Ceidda, Salvatore Papasergi, Patrizia Guarneri, Salvatore Cuzzocrea, Emanuela Esposito, Santa Viola
  • Patent number: 11266740
    Abstract: Nanoparticles having radially-oriented pores are fabricated from a noble metal. The pores have a specific geometrical shape, such as a circle, triangle, hexagon or other polygon. The nanoparticles are administered to a subject to form a nanoparticle-loaded tumor, which is targeted with a radiation beam as part of a radiotherapeutic treatment. The pores redirect photons of the radiation beam to intensify and enhance the dose received by tumor cells, while concomitantly reducing the dose received by surrounding cells and/or tissues. The nanoparticles may be combined with a radiosensitizing drug or agent, administered together or separately, to form a dose-enhancement composition that further intensifies the received dose of radiation at the target.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: March 8, 2022
    Inventor: Fouad Abdulaziz Abolaban
  • Patent number: 11260018
    Abstract: The present disclosure generally relates to approaches for improving water absorption and retention by the skin's surface. In particular, the disclosure provides compositions and methods for preparing mixtures comprised of ethoxylated oils and water or mixtures comprised of micro or nano emulsions and water, which provide enhanced skin hydration or moisturization to a subject.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: March 1, 2022
    Inventors: Frederick L. Jordan, Chris Jordan
  • Patent number: 11260109
    Abstract: The present invention relates to a product and method of using albumin nanoparticles for augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo. A predetermined amount of the albumin nanoparticle suspension is administered to a patient before or after an onset of at least one condition. The condition is one that can benefit from a healing effect of the stem cells or precursor cells. A function of the stem cells or precursor cells are augmented or improved by the albumin spheres to repair cellular or tissue damage, resulting in decreasing mortality or morbidity of the patient. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 1, 2022
    Inventor: Richard C. K. Yen
  • Patent number: 11261216
    Abstract: Genetically modified HBc polypeptides are provided.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: March 1, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: James R. Swartz, Rinchu Mathew, Marcus John Rohovie, Maya Nagasawa
  • Patent number: 11255848
    Abstract: A composition can include a complex, where the complex includes a photoluminescent nanostructure and a polymer free from selective binding to an analyte, the polymer adsorbed on the photoluminescent nanostructure, and a selective binding site associated with the complex.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 22, 2022
    Inventors: Michael S. Strano, Jingqing Zhang, Paul Walter Barone, Daniel A. Heller, Jong-Ho Kim
  • Patent number: 11253464
    Abstract: Anhydrous compositions including from 3% to 15% by weight of at least one lipophilic gelling agent, from 10% to 50% by weight of fillers including at least 5% by weight of a first filler and at least 5% by weight of a second filler different from the first; and from 40% to 85% by weight of at least one fatty phase are provided.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: February 22, 2022
    Assignee: L'OREAL
    Inventors: Valerie Page, Sophie Guilbaud, Celine Demarcq
  • Patent number: 11253458
    Abstract: Disclosed is a personal care composition comprising: a) particle comprising chitosan salt at the outer surface of the particle; and b) silicone component selected from dimethicone, aminosilicone or a mixture thereof, wherein the silicone component has a viscosity of at least 5,000 cSt at 25° C.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 22, 2022
    Assignee: Conopco, Inc.
    Inventors: Christopher Clarkson Jones, Xiaoyun Pan, Su Yuan, Qiqing Zhang
  • Patent number: 11248907
    Abstract: A test block is formed of at least one profile block and one mating block, wherein the two blocks lying one on top of the other with varying thickness combinations are radiographed together, in order to ascertain, for the pairings of the materials in the respective thickness, in each case a reference value relating to their common radiographic properties.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: February 15, 2022
    Assignee: Wipotec GmbH
    Inventors: Ulrich Heil, Christian Bur
  • Patent number: 11235084
    Abstract: In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: February 1, 2022
    Assignee: Varian Medical Systems, Inc.
    Inventors: Hongxia Zeng, Bruce R. Forsyth, Hong Cao, Matthew R. DeWitt, Heidi Schwanz
  • Patent number: 11229603
    Abstract: This process manufactures a finished medicine that can be used against broad spectrum, Anti-Viral, Anti-Bacterial, Anti-Fungal, and Anti-parasitic disease conditions that attack the human body but not limited to other medical conditions and or other types of treatments use for animals other than humans.
    Type: Grant
    Filed: August 1, 2021
    Date of Patent: January 25, 2022
    Assignee: Reynolds Blue, LLC
    Inventors: Rodney Reynolds, Carmine Russo, Robert Reynolds
  • Patent number: 11229230
    Abstract: Provided herein are antioxidant-enriched multivitamin compositions comprising vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folic acid, vitamin B 12, biotin, pantothenic acid, zinc, selenium, coenzyme Q10, lutein, lycopene, and zeaxanthin for the treatment of fat malabsorption diseases such as cystic fibrosis. Also provided are methods of treating vitamin and micronutrient deficiencies in subjects suffering from cystic fibrosis by administering an antioxidant-enriched multivitamin composition.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: January 25, 2022
    Assignee: Callion Pharma, LLC
    Inventor: Konstantinos Andreas Papas
  • Patent number: 11213544
    Abstract: An application of alginate sulfate in the preparation of drugs and health care products for preventing and treating diseases caused by human papillomavirus. Alginate sulfate has a strong dose-dependent inhibitory effect on HPV infection through experiments, and alginate sulfate inhibited the expression of E6 and E7 genes and proteins in HPV-transformed Hela and Caski cells in a dose-dependent manner. The alginate sulfate can be developed into a drug or a health care product against human papillomavirus by systematic scientific experiments, which will have a good market application prospect.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: January 4, 2022
    Inventors: Huashi Guan, Shixin Wang, Wei Wang, Chunxia Li, Pengli Li, Hongguang Wang, Xuan Xia, Xiaoshuang Zhang
  • Patent number: 11202785
    Abstract: Provided herein are compositions (e,g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: December 21, 2021
    Assignee: Lennham Pharmaceuticals, Inc.
    Inventors: Bradford C. Sippy, Benjamin D. Enerson
  • Patent number: 11197478
    Abstract: A method of controlling anthracnose caused by Colletotrichum on tropical fruits, tropical fruit plants or cultivars or plant parts or locus thereof is described. The method comprises the steps of contacting the tropical fruit plant or cultivar in need of treatment with an agrochemical composition comprising an effective amount of a guanidine or a salt and/or solvate thereof. The contacting step may be repeated one or more times at a fixed interval. The guanidine may be dodine, iminoctadine trialbesilate, iminoctadine triacetate, guazatine, salts and/or solvates of any of the foregoing and combinations of one or more of the foregoing.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: December 14, 2021
    Inventors: Lara Ramaekers, Maurilio Flores Lopez
  • Patent number: 11191718
    Abstract: The present invention provides an ophthalmic gel and a preparation method thereof. The ophthalmic gel comprises: an antibiotic; a nanocarrier, wherein the nanocarrier is used to load the antibiotic; and a biodegradable matrix, wherein the biodegradable matrix is compatible with the nanocarrier to carry the nanocarrier. When the ophthalmic gel of the present invention is applied to the surface of the cornea and conjunctiva of the eyes, the biodegradable matrix is automatically degraded and the nanocarrier carried by the biodegradable matrix will slowly release the antibiotic, loaded in the nanocarrier, at an appropriate rate to overcome the high-frequency use of general ophthalmic drugs and easily caused blurred vision; the present invention further comprises an ophthalmic gel preparation method.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: December 7, 2021
    Inventors: Ming-Cheng Chang, Tsai-Yueh Luo, Cheng-Liang Peng, Kuan-Yin Chen
  • Patent number: 11191731
    Abstract: A film coating composition comprising a cellulosic polymer, an opacifying agent, and a fatty acid is disclosed herein. Also disclosed is a film coating composition comprising a cellulosic polymer, an opacifying agent, a plasticizing agent, and a polyol. The disclosed film coating compositions may be mixed with a solvent to produce a film coating suspension. The film coating suspension can be applied to a substrate, such as a nutritional supplement, pharmaceutical, tablet, capsule, softgel, granule, particle, food confectionary form, agricultural seed, and the like to form a film coating on the substrate. Methods of coating a substrate with the film coating suspensions are also provided.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: December 7, 2021
    Assignee: Sensient Colors LLC
    Inventors: Beverly A. Schad, Brian K. Cheng